Results 191 to 200 of about 4,006,149 (207)

Abstract 5245: Identification and characterization of the IDO1 inhibitor LY3381916

Experimental and Molecular Therapeutics, 2018
Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-dependent enzyme that catalyzes the initial and rate-limiting step of tryptophan catabolism resulting in the local depletion of tryptophan and the concomitant production of kynurenine, both of which are ...
F. Dorsey, K. Benhadji, Lillian Sams, D. Young, J. F. Schindler, Karen L. Huss, A. Nikolayev, C. Carpenito, D. Clawson, Bonita D. Jones, Andrew L. Faber, James E. Thomas, S. Haney, Gai-Ying Zhao, W. Mcmillen, T. Smeal, D. J. Sall, M. Kalos, S. Geeganage, James R. Henry   +19 more
semanticscholar   +1 more source

IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.

Cancer Letters, 2021
Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzing the conversion of tryptophan (Trp) to kynurenine (Kyn) in kynurenine pathway (KP) is involved in the immunosuppression in pancreatic cancer (PC), but the value of IDO1 as an independent prognostic marker ...
Heng Liang, Tianqi Li, Xin Fang, Zikang Xing, Shengnan Zhang, Lei Shi, Weirui Li, Leilei Guo, Chunxiang Kuang, Hongrui Liu, Qing Yang   +10 more
semanticscholar   +1 more source

Abstract 5555: Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers

Clinical research, 2018
Indoleamine-2,3-dioxygenase (IDO1) is well-recognized as an important target for immunotherapeutic intervention. Growing interests on this target have been demonstrated by the recent expansion of enthusiasms to inhibit the Trp-to-Kyn pathway as a means ...
Shou-Jun Chen, Feng-Tao Liu, Hong-Li Guo, Shu-Wen Ren, Yikun Zeng, W. Yang, P. Qing, Tao Chen, Fengmin Zhou, Guocheng Li, Mingliang Sun, X. Ye, Xing-Zhong Zhang, Panhu Zhu, Hui Xu, Pei Li, Donghai Li, Z. Jie, Huanping Li, Shuda Zhao, Jiang-Jing Tan, He-Ping Yang, Long-Sheng Wang, Fang Liu, Guang-Bo Fu, Jian-Qing Du, Hong-Ye Yang, Wenting Xue, Pei Wang, Lanjie Guo, Lu Wang, Qun Li, Yu-Xun Wang, Daxing Gao   +33 more
semanticscholar   +1 more source

Determination of epacadostat, a novel IDO1 inhibitor in mouse plasma by LC-MS/MS and its application to a pharmacokinetic study in mice.

Biomedical chromotography, 2016
A sensitive, specific and rapid LC-ESI-MS/MS method has been developed and validated for the quantification of epacadostat in mouse plasma using tolbutamide as an internal standard (IS) as per regulatory guidelines.
Vinay Kumar Dhiman, K. Giri, S. S, Mohd Zainuddin, S. Rajagopal, R. Mullangi   +5 more
semanticscholar   +1 more source

Abstract 2736: Preclinical pharmacologic and pharmacodynamic studies of a novel and potent IDO1 inhibitor D-0751

Immunology, 2018
Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-containing enzyme that catalyzes the degradation of the essential amino acid L-tryptophan to kynurenine. It plays an important role in the initial and rate-limiting step in the breakdown of tryptophan.
Yao-Lin Wang, Zhe Shi, Zixing Han, Zhenwu Wang, Yue-Heng Jiang, Xing Dai   +5 more
semanticscholar   +1 more source

Tumor and dendritic cell dual-targeting nanocarriers maximize the therapeutic potential of IDO1 inhibitor in vivo

Nano Reseach, 2022
Tong Yu, Xiangyu Jin, Fang-ying Yu, Xi-Qin Yang, Ying-Ping Zeng, Ting-Ting Meng, Hong Yuan, Fu-Qiang Hu   +7 more
semanticscholar   +1 more source

A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma

Investigational new drugs, 2020
D. Reardon, A. Desjardins, O. Rixe, T. Cloughesy, S. Alekar, Jason H. Williams, Ray Li, C. Taylor, A. Lassman   +8 more
semanticscholar   +1 more source

Imidazo[2,1-b]thiazole based indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor: Structure based design, synthesis, bio-evaluation and docking studies

Bioorganic and Medicinal Chemistry Letters, 2023
Deepak Salunke, Debasis Manna, Surendra Nimesh   +2 more
exaly  

Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy

European Journal of Medicinal Chemistry, 2022
Yuxi Wang, Changyu Ren, Jifa Zhang
exaly  

Discovery of a Novel Scaffold as an Indoleamine 2,3‐Dioxygenase 1 (IDO1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B

ChemMedChem, 2016
Zenyu Shiokawa, Emi Kashiwabara, Daisuke Yoshidome, K. Fukase, S. Inuki, Y. Fujimoto   +5 more
semanticscholar   +1 more source